

# UNDERSTANDING IEI:

## LINKING PATHOPHYSIOLOGY WITH EVOLVING THERAPEUTIC STRATEGIES

**Thursday 22 - Friday 23 January 2026, 9:30-17:45 GMT**

### Thursday 22 January

<b>9:00-9:30</b>	<b>Registration for those attending in person</b> (Ryan Connolly Room, Zayed Centre for Research, 20c Guilford Street, London, WC1N 1DZ). <b>Those joining online to log in at 9:28</b>	
<b>9:30-13:30</b>	<b>Session 1: HLH</b>	
<b>9:30-9:50</b>	Pathophysiology and new classification of HLH	<b>Anupama Rao</b> , Consultant in Paediatric Haematology, GOSH, UK
<b>9:50-10:10</b>	In-depth understanding of Rab-27 immune defect	<b>Maaïke Kusters</b> , Consultant in Paediatric Immunology, GOSH, UK
<b>10:10-10:30</b>	Inflammasomopathy in monogenic HLH	<b>Elizabeth Rivers</b> , Consultant in Paediatric Immunology, GOSH, UK
<b>10:30-10:50</b>	Diagnostics for monogenic HLH	<b>Kimberly Gilmour</b> , Director of Immunology Laboratory services, GOSH, UK
<b>10:50-11:00</b>	Q&A	
<b>11:00-11:30</b>	<b>Break</b>	
<b>11:30-12:00</b>	HLH-2004: Diagnostics and treatment revisited	<b>Jan-Ing Henter</b> , Professor of Clinical Paediatric Oncology, Karolinska University Hospital, Sweden
<b>12:00-12:30</b>	Alemtuzumab as first line therapy for monogenic HLH	<b>Despina Moshous</b> , Consultant in Paediatric Immunology, Necker-Enfants Malades University Hospital, France
<b>12:30-13:00</b>	Targeting HLH with biologics: what is working? and what is next?	<b>Reem Elfeky</b> , Consultant in Paediatric Immunology, GOSH, UK
<b>13:00-13:30</b>	Q&A	
<b>13:30-14:30</b>	<b>Lunch break</b>	
<b>14:30-17:30</b>	<b>Session 2: DADA2</b>	
<b>14:30-15:00</b>	Linking pathophysiology and clinical presentation of DADA2 to the development of novel therapies	<b>Despina Eleftheriou</b> , Consultant in Paediatric rheumatology, GOSH; Professor of Paediatric rheumatology, UCL GOS ICH, UK
<b>15:00-15:30</b>	Etanercept for DADA2: Firefighter or bridge for HSCT	<b>Isabelle Meyts</b> , Consultant in Paediatric Haemato-oncology, University Ziekenhuis Leuven, Belgium
<b>15:30-16:00</b>	Gene therapy in DADA2: are we close?	<b>Federica Barzaghi</b> , Consultant in Paediatric Immunology, Immunohaematology Unit, San Raffaele Hospital, Italy
<b>16:00-16:10</b>	ADA2 enzyme assay and utility for confirming VUSes and monitoring engraftment post HSCT	<b>Mark Davis</b> , Healthcare Scientist - Immunology, GOSH, UK
<b>16:10-16:30</b>	Q&A	
<b>16:30-17:00</b>	<b>Break</b>	
<b>17:00-17:30</b>	Interactive case presentations	
<b>17:30</b>	<b>End of day 1</b>	

# UNDERSTANDING IEI:

## LINKING PATHOPHYSIOLOGY WITH EVOLVING THERAPEUTIC STRATEGIES

**Friday 23 January**

<b>9:15-9:30</b>	<b>Arrival for those attending in person</b> (Ryan Connolly Room, Zayed Centre for Research, 20c Guilford Street, London, WC1N 1DZ). <b>Those joining online to log in at 9:28</b>	
<b>9:30-13:30</b>	<b>Session 3: IEI with Immune dysregulation</b>	
<b>9:30-10:00</b>	Therapeutic intervention for Gain- and Loss-of-function STAT1 mutations	<b>Catharina Schütz</b> , Professor of Paediatric Immunology in University Hospital Carl Gustav Carus Technische Universität Dresden, Germany
<b>10:00-10:30</b>	Comparative study Sirolimus versus Leniolisib in APDS1 and APDS2	<b>Beatrice Rivalta</b> , Paediatric Immunologist, Department of Clinical Immunology and Vaccinology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy
<b>10:30-11:00</b>	Position of Abatacept as targeted therapy for CTLA4 and LRBA defects	<b>Safa Baris</b> , Professor in Paediatric Immunology, Marmara University Medical Faculty, Turkey
<b>11:00-11:30</b>	Q&A	
<b>11:30-12:00</b>	<b>Break</b>	
<b>12:00-12:30</b>	Gene therapy in IPEX: Opening new doors	<b>Rosa Bacchetta</b> , Professor (Research) of Paediatrics (Stem Cell Transplantation), Stanford University School of Medicine, USA
<b>12:30-13:00</b>	Pharmacist role in the era of personalised medicine- opportunities and challenges	<b>Fan Ing Cheng</b> , Senior clinical pharmacist in Immunology, GOSH, UK
<b>13:00-13:30</b>	Q&A	
<b>13:30-14:30</b>	<b>Lunch break</b>	
<b>14:30-17:30</b>	<b>Session 4: Secondary immunodeficiency</b>	
<b>14:30-15:00</b>	Is it CVID or secondary immunodeficiency- how can you tell?	<b>Susan Tadros</b> , Consultant in Adult Immunology, Royal Free London, UK
<b>15:00-15:30</b>	Biological therapies and immunosuppression: A guide to risk mitigation and management approach	<b>David Lowe</b> , Consultant in Adult Immunology, Royal Free London, UK
<b>15:30-16:00</b>	Interactive case presentation and pharmaceutical symposium	
<b>16:00-16:30</b>	<b>Break</b>	
<b>16:30-18:00</b>	<b>Session 5: Laboratory diagnostics</b>	
<b>16:30-16:45</b>	Interferon stimulated gene assay for diagnosing and monitoring interferonopathies	<b>Mercedes Selby</b> , Senior Biomedical Scientist, GOSH, UK
<b>16:45-17:00</b>	Cytokines and access to targeted therapy	<b>Arnold Awuah</b> , Clinical Scientist Trainee in Immunology, GOSH, UK
<b>17:00-17:15</b>	Advances in phosphorylation assays	<b>Micol Ferro</b> , Senior Healthcare Scientist and Clinical Scientist, GOSH, UK
<b>17:15-17:30</b>	Th17 as a biomarker for immune dysregulation	<b>Annabelle Lea Mai</b> , Laboratory Manager, GOSH, UK
<b>17:30-17:45</b>	Translating assays from R&D into clinical use	<b>Rachel Peraj</b> , Healthcare Scientist, GOSH, UK
<b>17:45</b>	<b>End</b>	

Endorsed by:



With thanks to our sponsor:

